Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alnylam Pharmaceuticals
Participants will receive ALN-AGT01 or placebo for the first 6 months of the 12-month double-blind (DB) treatment period. Participants randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial ALN-AGT01 regimens until the end of the 12-month DB treatment period. Participants randomized to ALN-AGT01 regimens will remain on their originally assigned regimens through remainder of the study.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication
You may not be if
Secondary hypertension, orthostatic hypotension
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2× upper limit of normal (ULN)
Elevated potassium \>5 mEq/L
Estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m\^2
Received an investigational agent within the last 30 days
Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus
History of any cardiovascular event within 6 months prior to randomization
